Nintedanib for systemic sclerosis–associated interstitial lung disease
N Engl J Med 2019;380:2518–28 doi: 10.1056/NEJMoa1903076
Distler et al. reported that the annual rate of decline in FVC through Week 52 was lower with nintedanib than with placebo among patients with ILD associated with SSc. No clinical benefit of nintedanib was observed for other manifestations of SSc. The safety profile of nintedanib was similar to that observed in patients with idiopathic pulmonary fibrosis.